AprilBio Co.,Ltd. (KOSDAQ:397030)

Revenue by Segment

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2022	FY 2021	FY 2019	FY 2018
Period Ending	Dec 31, 2024	Dec 31, 2022	Dec 31, 2021	Dec 31, 2019	Dec 31, 2018
Bio Innovation and New Drug Development	27.51B
Bio Innovation and New Drug Development Growth	13657.00%

Revenue by Geography

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2022	FY 2021	FY 2019	FY 2018
Period Ending	Dec 31, 2024	Dec 31, 2022	Dec 31, 2021	Dec 31, 2019	Dec 31, 2018
South Korea	27.51B
South Korea Growth	13657.00%

Data Source: Finnhub Last updated: Mar 31, 2026

Financial data is provided by Finnhub and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 12, 2026

Data Sources Report a data error